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ABSTRACT  
Maturation of bovine immature oocyte requires cytoplasmic polyadenylation and synthesis of a 34 
number of proteins involved in meiotic progression and metaphase-II arrest. Aurora serine-
threonine kinases - localized to centrosomes, chromosomes and midbody - regulate 36 
chromosome segregation and cytokinesis in somatic cells. In frog and mice oocytes, Aurora A 
regulates polyadenylation-dependent translation of several mRNAs like MOS and CCNB1, 38 
presumably by phosphorylating CPEB, and Aurora B phosphorylates histone H3 during 
meiosis. Here, we analyzed the expression of three Aurora kinases AURKA, AURKB and 40 
AURKC in bovine oocytes during meiosis and early embryogenesis by RT-qPCR and 
immunodetection. Aurora A was the most abundant in oocytes, as compared with AURKB and 42 
AURKC mRNA and protein levels. AURKA protein progressively accumulated in the oocyte 
cytoplasm during antral follicle growth and in vitro maturation. AURKB associated with 44 
metaphase chromosomes. AURKB, AURKC and Thr-phosphorylated AURKA were detected 
at a contractile ring/midbody during the first polar body extrusion. CPEB, localized in oocyte 46 
cytoplasm, was hyper-phosphorylated during prophase/metaphase-I transition. Most of CPEB 
was degraded in metaphase-II oocytes and remnants remained localized at a contractile ring. 48 
Roscovitine, U0126 and metformin inhibited meiotic divisions; they all induced a decrease of 
CCNB1 and phospho-MAPK3/1 levels and prevented CPEB degradation. However, only 50 
metformin depleted AURKA. The Aurora kinases inhibitor VX680 at 100 nM did not inhibit 
meiosis but led to multi-nuclear oocytes due to the polar body extrusion failure. Taken 52 
together, in bovine oocytes, Aurora kinases participate in regulating the segregation of the 
chromosomes, metaphase-II maintenance and the polar body formation during meiosis.54 
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INRODUCTION 
In mammal ovaries, oocytes are arrested in prophase of the first meiotic division and become 56 
transcriptionally silent when they reach the full size and enter in pre-ovulatory meiotic 
maturation process. Nuclear meiotic maturation of oocytes includes the condensation of 58 
chromosomes, germinal vesicle breakdown (GVBD), progression through metaphase-I (MI), 
and arrest at metaphase-II (MII).  In cows, full-grown oocytes extracted from more than 2-mm 60 
follicles are capable to resume meiosis in vitro and then to be fertilized and to develop up to 
blastocyst in vitro [1]. Oocyte maturation process involves the coordinated action of several 62 
kinases. Mitogen activated protein kinases (MAPKs) and maturation promoting factor (MPF) - 
a complex of cyclin B1 (CCNB1) and cell cycle controller p34 kinase CDC2 (named also 64 
CDK1, cyclin-dependent kinase 1), constituted the main signalling pathways of oocyte 
maturation. Two forms of serine-threonine MAPKs, MAPK1 and MAPK3 (also known as 66 
p42MAPK/ERK2 and p44MAPK/ERK1 respectively) are present in mammalian oocytes, and 
they are at least partially activated by the upstream kinase named MOS. In bovine oocytes, 68 
MPF and MAPK3/1 activation precedes GVBD during in vitro maturation (IVM) [2]. A 
significant increase in overall protein synthesis occurs in bovine oocytes in accordance with 70 
GVBD at 6-10 hours after beginning of IVM and then it declines and reaches the basal level at 
the MII stage [3]. This process is accompanied by the polyadenylation of mRNA until the MII  72 
[4]. A number of proteins are synthesized de novo in bovine oocytes during IVM [5], including 
CCNB1 [6],  and MOS [7]. In Xenopus and mice oocytes, cytoplasmic polyadenylation and 74 
sequential translation of such mRNA are mediated by CPEB, a protein which binds to 
cytoplasm polyadenylation element (CPE) - an U-rich cis-element present in 3’-untranslated 76 
region of a number of mRNAs, such as MOS or CCNB1 [8,9]. In Xenopus, activation of CPEB 
is triggered by the serine-threonine kinase AURKA [10],[11] which is the homologue of yeast 78 
IpL1 and Drosophila Aurora, regulating the mitotic progression in eukaryotic cells [12]. 
However, it is not clear whether CPEB activation by AURKA triggers the further cascade of 80 
MAPKs phosphorylations leading to MPF activation and nuclear maturation [13], or whether 
AURKA itself needs the active MPF to be phosphorylated and activated, while these events are 82 
independent of the MOS/MAPK pathway [14]. In mice oocytes cytoplasm, AURKA is 
colocalized with CPEB, CPSF (cleavage and polyadenylation specificity factor), PAP (polyA 84 
polymerase) and maskin - factors known to control polyadenylation and translation, and was 
reported to mediate CPEB phosphorylation in MI [15]. Phosphorylated CPEB activation 86 
stimulates both polyadenylation and translation of several mRNAs essential for oocyte 
maturation, including MOS, CCNB1 and SCP1/SCP3 (synaptonemal complex proteins 1 and 88 
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3) in mice [16]. AURKA might also be involved in microtubule assembly and nuclear activity 
in mice oocytes [17].  90 
In higher mammals including domestic animals and human, only little is known 
regarding the involvement of Aurora kinases in meiosis. In contrast, in somatic cells, 92 
Aurora kinases were identified as important regulators of mitotic divisions. Three 
Aurora kinases - AURKA, AURKB and AURKC exist in mammals. They share a very 94 
similar kinase catalytic domain and their expression is cell cycle-regulated with a 
maximal protein level at G2/M. The intracellular localizations of Aurora kinases are 96 
different at least between AURKA and AURKB/AURKC [18]. AURKA localizes to 
centrosomes and spindle poles [19], [20]. AURKA is required for centrosome 98 
maturation and separation, bipolar spindle assembly, chromosomal alignment on the 
metaphase plate and for cytokinesis (review [21]). AURKB is a chromosome passenger 100 
protein essential for chromosome condensation and cytokinesis completion.  
It localizes to chromosome kinetochores during prophase and metaphase and to the 102 
midbody during the anaphase and telophase [22, 23]. AURKC like AURKB is a 
chromosome passenger protein [24], it associates with AURKB and Survivin [25], [19]. 104 
In cancer cells, Aurora proteins accumulate in cytoplasm [26, 27]. Aurora kinases 
activity is regulated by phosphorylation/dephosphorylation of several residues [28], 106 
[29]. Glycogen synthase kinase-3 (GSK-3) remains the only kinase identified as an 
upstream activator of Aurora [30]. Aurora kinases could also be activated by 108 
autophosphorylation when associated with some of its substrates, like a motor binding 
protein TPX2 (microtubule-associated protein homolog) for AURKA [31] or INCENP 110 
(inner centromere protein) for AURKB [29]. In turn, Aurora kinases phosphorylate a 
large number of proteins, including kinesin-like motor proteins, spindle apparatus 112 
proteins, kinetochore proteins, histones and tumor suppressor proteins such as p53 (for 
review [18]).  114 
We previously found that in bovine oocytes, AURKA mRNA was abundantly highly expressed 
[32]. We also previously showed AURKA protein level increased during IVM in bovine 116 
oocyte and this increase was not affected by inhibition of MPF activity [33]. In porcine 
oocytes, Thr-phosphorylated AURKB level correlated with histone H3 phosphorylation on 118 
Ser10 [34]. In human oocyte, AURKC mRNA was reported to be over-expressed as compared 
to cumulus cells [35].  120 
The aim of this study was to establish for the first time the spatio-temporal expression patterns 
of three Aurora kinases in bovine oocytes during meiotic maturation in order to clarify their 122 
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roles in meiosis. First, we analyzed the relative expression of AURKA, AURKB and AURKC 
mRNA by real time RT-PCR and the localization of the corresponding proteins by 124 
immunocytochemistry in bovine oocytes and preimplantation embryos. Second, mRNA and 
protein expression patterns of several main actors of meiotic progression such as CCNB1, 126 
CDC2, MOS and CPEB were studied in parallel with AURKA Thr-phosphorylation 
throughout IVM. Third, the effects of meiotic inhibitors Roscovitine, U0126 and Metformin on 128 
the levels of AURKA, phospho-MAPK3/1, CCNB1, CDC2 and CPEB were observed. Finally, 
the effects of VX680, the specific inhibitor of Aurora kinase activity, on meiosis progression 130 
were analyzed.  
MATERIAL AND METHODS 132 
Materials 
TCM199 culture medium, Gentamicin, Epidermial Growth Factor (EGF), fetal calf serum, 134 
MEK inhibitor U0126 and Metformin were from Sigma (Saint Quentin Fallavier, France). 
Cyclin-dependent kinase inhibitor Roscovitine was provided by Dr L. Meijer (Centre National 136 
de la Recherche Scientifique, Station Biologique de Roscoff, France).  VX680 inhibitor of 
Aurora kinase activity was from CAVA Technology (San Diego, USA). 138 
 
Oocytes, embryos and other tissues collections. 140 
Cattle ovaries were collected at slaughterhouse. Cumulus-oocyte complexes (COC) were 
obtained by aspiration of 3-6 mm antral follicles. In average, 14 + 4 good quality COC could 142 
be obtained from one slaughtered cow. COC with more than 3 layers of compact cumulus cells 
around the oocyte were selected and washed several times in TCM199/Hepes medium 144 
supplemented with 50 mg/l of Gentamycin. Groups of 30 to 60 COC were subjected to in vitro 
maturation (IVM) in 500 µl of TCM199 medium supplemented with EGF (10 ng/ml) and 10% 146 
of fetal calf serum during 24 hours at 39°C in a humidified atmosphere of 5% CO2 in air.  
In experiments with meiotic inhibitors, the substances were added in culture medium just 148 
before IVM.  U0126 and Roscovitine were used at final concentration of 100µM and 50µM, 
respectively. Metformin was added at 10 mM, and it was reported that this concentration did 150 
not affect the cell viability [36]. We used VX680 at concentration of 100 nM, which is close to 
a half-maximal inhibitory concentration (IC50  15-113 nM) for the proliferation of a variety of 152 
human cell types [37], and also at 1 µM – the concentration that was used in studies on mouse 
and human cell lines (1 and 10 µM) [38].   154 
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Routinely, the oocytes were denuded from COC by mechanical separation of cumulus cells 
either just after collection from ovaries (immature oocytes, IO, at germinal vesicle stage, GV) 156 
or after 3, 6, 10, 14 and 22-24 hours of IVM culture. Oocytes were rinsed in PBS and then 
frozen in liquid nitrogen and stored until RNA or protein extraction. Meiotic status of oocytes 158 
at different time of maturation was verified by lamin A/C immunofluorescence and chromatin 
labelling with Hoechst33342 (Sigma, 1µg/ml), followed by microscopic observation.  160 
For in vitro preimplantation embryos production, COC were subjected to IVM for 22 hours, 
and subsequently to in vitro fertilization and embryo development as described earlier [32]. 162 
Groups of 10 or 20 embryos at 1-Cell, 2-Cell, 4-Cell, 5 to 8-Cell, morula and blastocyst stages 
were collected and either fixed for immunofluorescence analysis, or frozen in liquid nitrogen. 164 
Biopsies (0.5 g) from ovary and testis were collected at INRA local slaughterhouse from two 
adult cows and two bulls. Calf skin fibroblast primary culture cells and cumulus cells were 166 
used for protein extraction. All samples were frozen in liquid nitrogen and kept at -80°C before 
experiments.  168 
 
RNA and cDNA preparation and analysis.  170 
 
Total RNA preparation 172 
Total RNA was extracted from bovine oocytes, embryos and biopsies of adult ovary and testis 
by using TriZol reagent following the manufacturer’s instructions (Invitrogen, Cergy Pontoise, 174 
France). To avoid the contamination with genomic DNA, total RNA preparations were treated 
by RQ1 DNAse (Promega) as described in manufacturer’s protocol.  176 
 
AURKA, AURKB and AURKC cDNA sequences analysis. 178 
Full-length Aurora A (gene AURKA) cDNA was obtained by using SMART RACE cDNA 
Amplification Kit (Ozyme), 5’ and 3’ cDNA fragments were cloned into pCRII-dual promoter 180 
vector using the TA cloning kit (Invitrogen) and sequenced by Macrogen Company (Seoul, 
South Korea). Deduced cDNA and protein sequences were deposed in Genbank (accession 182 
number DQ334808). Sequences for bovine Aurora B (AURKB) and Aurora C (AURKC) were 
found in GenBank (accession numbers are NM_183084 and XM_870932, respectively).  The 184 
sequences were analyzed using the software package proposed by Infobiogen [39]. Alignments 
were performed using BLAST [40] and Multalin [41]. Deduced protein sequences were 186 
analyzed through Interpro website [42] and Simple Modular Architecture Research Tool 
(SMART) [43].  188 
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RT-PCR 190 
Reverse transcription (RT) was performed on RNA amounts equivalent to 5 or 10 oocytes or 
embryos, or 1 µg of total RNA from tissue biopsies. Complementary DNA was extended from 192 
oligo (dT)15 primers during 1 hour at 37°C by mouse Moloney leukaemia virus reverse 
transcriptase (Invitrogen) as described in user manual. For RT-PCR analysis we used as a 194 
template the cDNA equivalent to 5% of one oocyte/embryo reversed RNA (1% of total RT 
reaction). For ovary and testis, 1/20 of the reverse transcription products were used (50 ng of 196 
reversed RNA equivalent). PCR were performed using reagents from Interchim (Montluçon, 
France). In negative control reaction, RNA amount equivalent to 1 oocyte or 125 ng of tissue 198 
RNA were directly subjected to PCR with specific primers. As positive control of cDNA 
quality, the β-actin specific PCR was performed for all the samples. Primers sequences are 200 
listed in Table 1. To verify the specificity of amplified fragments, PCR products were cloned 
and sequenced. 202 
Real-time PCR 
For real time RT-PCR analysis, cDNA was extended from RNA from 10 oocytes by MMLV 204 
reverse transcriptase (Invitrogen) in the presence of 20 ng of oligo (dT)15  and 2 ng of 18S-
antisense-RT primer per reaction. Real-time PCR was performed on MyiQ apparatus (Bio-Rad 206 
Laboratories, Marnes La Coquette, France) using the cDNA quantity equivalent to 5% of one 
oocyte/embryo per reaction. Reactions were performed in triplicate by using a “Real-time PCR 208 
kit” provided with a SYBR Green fluorophore (Bio-Rad) according to the manufacturer 
instructions and by using the robotic distributor (Eppendorf). One pg of luciferase mRNA was 210 
added to each group of 10 oocytes or embryos before RNA extraction and was used as an 
external control of RNA extraction and cDNA quality. Four independent pools of RNA were 212 
analyzed for each stage of oocyte maturation and embryo development. For each gene 
examined, a standard curve, consisting of corresponding plasmid DNA fragments purified from 214 
with QIAquick PCR Purification kit (Qiagen) and diluted from 1 pg to 0.1 fg, was included in 
each run. Correlation coefficients and PCR efficiencies were not less than 0.998 and 85 %, 216 
respectively. The median values of reaction triplicates were considered. Different approaches 
were applied for relative quantification of target polyA mRNA.  1) The relative AURKA, 218 
AURKB and AURKC mRNA abundance in oocyte, blastocyst and testis was compared in 
relation to the quantities of correspondent amplified products in fg obtained from the same 220 
cDNA sample. 2) The relative abundance of target mRNA in oocytes at different stages of 
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maturation was calculated relatively to those of 18S rRNA, internal reference gene, since its 222 
level did not change during IVM in bovine oocytes [44]. 3) The relative abundance of AURKA 
mRNA in embryos at different stages of development was calculated relatively to the external 224 
reference, luciferase polyA RNA which was added prior RNA extraction.  
In all experiments, the mean value obtained for T0 immature oocytes was considered as 1. 226 
One-way ANOVA test were performed for statistical analysis of data. Difference was 
considered significant at P<0.05.  228 
Protein analysis  
Antibodies  230 
Monoclonal mouse antibody against recombinant full-length human Aurora A kinase was 
produced and characterized earlier [45]. Human Aurora B (ARK-2, H-75), CPEB (H-300) and 232 
MAPK42 (MAPK1 or ERK2, C14) rabbit polyclonal antibodies were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA).  Rabbit polyclonal to phospho-Thr288 Aurora A 234 
antibody was from Abcam (Cambridge, UK). Phospho-p44/42 MAPK rabbit polyclonal 
antibody (MAPK3/1 phosphorylated at Thr202/Tyr204) was purchased from Cell Signalling 236 
(Danvers, MA). Alpha-tubulin (TUBA) monoclonal antibody (clone DM1) and Texas Red-
conjugated goat anti-mouse antibody were from Sigma (Saint Quentin Fallavier). Antibodies 238 
against human Aurora C and phosho-Ser10 histone H3 were kindly provided by Dr. Y. Arlot 
(UMR6061 CNRS, France). Cyclin B1 monoclonal antibody (clone Ab-3), horseradish 240 
peroxidase (HRP) conjugated rabbit anti-mouse, goat anti-rabbit and goat anti-mouse IgG 
antibodies were purchased from Lab Vision (Fremont, CA). Lamin A/C monoclonal antibody 242 
was from Ozyme, (Saint Quentin Yvelines, France); Alexa Fluor®488 goat anti-rabbit IgG and 
Alexa Fluor®594 goat anti-mouse IgG were from Molecular probes (USA).  244 
Western immunoblotting 
Groups of definite number of bovine oocytes or embryos were frozen in 20 µl of Tris-saline-246 
EGTA composition buffer pH 7.5 supplemented with 2 mM sodium ortovanadate and 1 µl/ml 
of protease inhibitor cocktail (Sigma) and than thawed-frozen three times by rapid incubation 248 
in liquid nitrogen followed by warm water bath at 30°C. In some experiences, 
dephosphorylation of proteins on serine, threonine and tyrosine residues was performed by 250 
using the Lambda Protein Phosphatase (λ-PPase, Sigma). Oocyte were collected in 20 µl of 1x 
λ-PPase reaction buffer (50 mM, Tris-HCl, 0.1mM Na-EGTA, 5mM DTT, 0.01 Brij , 2mM 252 
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MnCl2 ), thawed-frozen three times and then incubated with 400 units of λ-PPase 1 hour at  
30°C. Before loading, concentrated reducing Laemmli buffer containing at final concentration 254 
80 mM dithiothreitol was added to all protein extracts and samples were boiled during 8 min.  
Proteins extracts were resolved on 10-12% SDS-PAGE gels and transferred to nitrocellulose 256 
membranes. Blots were blocked with 5% of dry milk in Tris-buffered saline / 0.1% Tween 20 
for one hour at room temperature and probed with the various antibodies overnight at 4°C. 258 
Dilutions were 1/1000 for AURKA, phospho-MAPK3/1, total MAPK3/1 and TUBA 
antibodies, 1/200 for CDC2, CCNB1 and AURKB, 1/2000 for CPEB. After extensive 260 
washings in 1xTBS/Tween 0.1%, immunoreactivity was detected using the appropriate HRP-
conjugated secondary antibodies (diluted 1:5000, incubation 1h at room temperature) and 262 
revealed by enhanced chemiluminescence ECL Plus kit according to the manufacturer's 
instructions (Amersham Biosciences, Orsay, France). Densitometry was performed by 264 
scanning the original radiographs and then analysing the bands with Scion Image software Beta 
4.0.2 (Fuji PhotoFilm, USA). At least three blots were analyzed for each experimental 266 
condition.  
  268 
Immunohistochemistry 
Ovarian biopsies were fixed for 12 hours in the solution containing 50% of saturated picric 270 
acid, 3.7% formaldehyde and 5% of acetic acid. After serial dehydration steps, the samples 
were embedded in paraffin and serially sectioned at a thickness of 7 µm. Sections were 272 
deparaffined, re-hydrated, and microwaved for 5 min in antigen unmasking solution (Vector 
Laboratories, Inc., AbCys, Paris, France) and then left to cool to room temperature. After 274 
washing in a PBS bath for 5 min, sections were immersed in peroxidase blocking reagent for 
10 min at room temperature to quench endogenous peroxidase activity (Dako Cytomation; 276 
Dako, Ely, UK). After three washes in a PBS bath for 5 min, sections were blocking with 5% 
goat serum in PBS for 20 min, followed by incubation overnight at 4°C with PBS/0.1% BSA 278 
containing AURKA antibody (dilution 1/100). After washing three times for 10 min, sections 
were incubated for 30 min at room temperature with a biotinylated goat anti-mouse antibody 280 
following by serial washing and 10 min staining in streptavidin peroxidase solution at room 
temperature as described in kit manual (both Lab Vision Corporation). Immunoreactivity was 282 
revealed by incubation at room temperature with 3, 3'-diaminobenzidine (Lab Vision 
Corporation). The slides were counterstained with hematoxylin, then dehydrated and mounted 284 
in Depex (Sigma). Negative controls were performed by replacing primary antibodies by 
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mouse IgG (Sigma) diluted in PBS/0.1% BSA at a final concentration of 2 µg/ml. Slides were 286 
observed using the Axioplan Zeisse transmission microscope.  
 288 
Immunofluorescence of bovine oocyte and embryos. 
For fluorescent analysis, oocytes and blastocysts were fixed for 10 min in the solution 290 
containing 50% of saturated picric acid, 3.7% of methanol stabilized-formaldehyde (Interchim) 
and 5% of acetic acid, and then washed 4 times 15 min in PBS supplemented with 0.2% BSA 292 
and once 30 min in PBS/0.2% BSA/0.1% Triton. For AURKA detection during early 
embryogenesis, oocytes and embryos at 1-Cell, 2-Cell, 4-Cell, 5/8-Cell, morula and blastocyst 294 
stages were fixed in cold methanol at -20°C for two hours, rehydrated through serial ethanol 
baths, and washed three times in PBS with 0.2% BSA and 0.01% Tween20. Blocking was 296 
performed in PBS/0.5% BSA supplemented with 10% of goat inactivated serum during 2 
hours. Overnight incubation with primary antibodies (diluted 1/100 for AURKA, AURKB and 298 
AURKC detection, 1/200 - 1/500 for phospho-Thr AURKA, 1/200 for phospho-Ser10 histone 
H3 and Lamin A/C) was performed at 4°C with constant shaking. At least four 30 min washes 300 
in PBS/0.2% BSA were done, and oocytes and embryos were incubated with corresponding 
secondary fluorochrome-conjugated antibody diluted at 1/200 for 1-2 hr at room temperature. 302 
Five 20 min washes were then performed. Oocytes and embryos were put on slides and 
mounted with Mowiol supplemented with DABCO anti-fading and 1µg/µl of Hoechst 33258 304 
or DAPI (Sigma). Immunofluorescence was observed using Axioplan Zeiss fluorescent 
microscope supplied with appropriate filters. 306 
 
ETHICS 308 
All procedures were approved by the Agricultural and Scientific Research Government 
Committees in accordance with the guidelines for Care and Use of Agricultural Animals in 310 
Agricultural Research and Teaching (approval A37801). 
 312 
RESULTS 
Three Aurora kinases are expressed in bovine oocyte.  314 
By RT-PCR using specific primers for Bos taurus Aurora kinase AURKA, AURKB and 
AURKC genes, we detected the cDNA fragments of expected sizes 234, 453 and 156 base 316 
pairs, respectively, in ovary, testis and in full grown immature oocytes isolated from 3-6 mm 
antral follicles (Figure 1A). AURKA was over-expressed in oocyte as compared with AURKB 318 
and AURKC relatively to β-actin amplification. To confirm this result, we quantified Aurora 
  11
kinases transcripts by real-time PCR. AURKA mRNA in oocytes was about twenty times more 320 
abundant than AURKB and AURKC, while in testis its level was only about two-fold higher 
(Figure 1B). AURKA and AURKC mRNA levels decreased dramatically in blastocyst, while 322 
AURKB was at similar level both in oocytes and blastocysts (Figure 1B).  
Analysis of amino acid sequences showed that bovine AURKA, AURKB and AURKC 324 
proteins shared the very similar C-terminal, containing serine-threonine kinase catalytic 
domain and RXXL destruction-box (D-box), but they differed in non-catalytic N-terminal 326 
domain (Supplementary data, figure 1A). Amino acid sequences of bovine Aurora kinases 
were highly homologous to those of human and mice as shown for AURKA (Supplementary 328 
data figure 1B). Predicted molecular weights of bovine Aurora proteins were 46 kDa, 40 kDa 
and 35 kDa for AURKA, AURKB and AURKC, respectively. In order to analyse the protein 330 
expression of AURKA, AURKB and AURKC in bovine oocytes and taking in account the 
extreme similarity in bovine and human Aurora kinases amino acid sequences, we used the 332 
antibodies to human Aurora proteins. Monoclonal antibody to human AURKA revealed a 
single protein at approximately 46 kDa in an extract prepared from 10 immature or mature 334 
oocytes (IO and MO) and in testis, but neither in cumulus (CC) and nor in fibroblasts cells (Fb) 
(Figure 1C). Human AURKB antibodies detected a protein of about 41 kDa in a protein extract 336 
prepared from fibroblast cells or from 50 mature oocytes but not in immature oocytes. In the 
same conditions, the antibody to human AURKC revealed the 35 kDa protein only in testis.    338 
Thus, three Aurora kinases were expressed in oocyte and AURKA was the most abundant form 
in immature oocytes. 340 
Localization of AURKA, AURKB and AURKC in bovine oocytes during meiosis and in 
expanded blastocysts.  342 
AURKA, Thr-phosphorylated AURKA, AURKB and AURKC were visualized by indirect 
immunofluorescent detection in bovine immature oocytes at the GV stage, in MI and MII 344 
oocytes and in embryos at the stage of blastocyst (Figure 2). In GV oocytes, AURKA was 
uniformly present in the whole cytoplasm (Figure 2 a). A subpopulation of AURKA 346 
phosphorylated on threonine residue was also detected, localized to numerous patches (figure 2 
b). No significant staining was observed when rabbit or/and mouse non-specific IgG were used 348 
instead of primary antibodies (figure 2 d).  In MI and MII oocytes, AURKA (figure 2 f, k) and 
phospho-Thr -AURKA (figure 2 g, l) were dispersed through the cytoplasm. Sometimes 350 
AURKA was concentrated around the metaphase-II plate (figure 2 k, MII insert), phospho-Thr-
AURKA immunoreactivity was not detected at that location (figure 2 l, MII insert).  Phospho-352 
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Thr-AURKA was concentrated at a contractile ring in the area that separates the polar body 
(PB) in oocytes at the telophase-1 and MII stages (figure 2 m; figure 5E  c). AURKA was not 354 
detected in the spindle poles in MI-MII oocytes (figure 2 f, g, k, l, m). However, in the 
expanded blastocyst, AURKA was preferentially concentrated in the spindle poles in 356 
metaphase, anaphase and in the newly forming poles in prophase cells (figure 2 p, insert M, 
An, P, respectively). Thr-phosphorylated AURKA was clearly detected in the spindle poles 358 
during metaphase in the blastocyst (M, asterisk-labeled insert in figure 2 p).  
AURKB was practically undetectable in the cytoplasm of immature oocytes (figure 2 c). In MI 360 
and MII oocytes, AURKB was detected at the chromosomes (figure 2 h, n) like in mitotic 
blastocyst cells (figure 2 r,  inserts M). AURKB was also detectable in the cytoplasm of MII 362 
and to a lesser extent in MI oocytes. However, AURKB was neither detected in a germinal 
vesicle nor in a polar body chromatin (figure 2 c, n). In contrast, AURKB was clearly 364 
associated with the contractile ring separating the polar body in MII oocyte (figure 2 n, insert 
PB) and with contractile ring/midzone between two blastomers during telophase/cytokinesis 366 
(figures 2 r, insert MZ). 
AURKC also showed a cytoplasmic localization throughout meiosis (figure 2 e, i, o). In MII 368 
oocytes, the protein was concentrated between the polar body and what might be the contractile 
ring (figure 2 o, insert PB). No significant AURKC specific labeling was detected in blastocyst 370 
cells. 
Taken together, three known Aurora kinase genes were expressed in bovine oocyte during 372 
progression of meiosis. AURKA protein showed the most intriguing expression pattern 
because it is quite different from the somatic cells. In contrast, AURKB in oocyte was 374 
associated to the metaphase chromosomes and to the midbody, as it was expected accordingly 
to the established pattern in mitotic cells. Faint level of AURKC did not allow continuing their 376 
study at protein level. Thus, we concentrated on the analysis of AURKA.  
 378 
AURKA expression pattern in ovary during folliculogenesis, in fertilized oocytes and in 
early embryos.  380 
We analyzed localization of AURKA in the oocytes throughout folliculogenesis on the 
paraffin-embedded sections of bovine ovaries (figure 3A). All main steps of folliculogenesis 382 
were found in the sections of the adult cow ovary: i) the primary follicles in which an oocyte is 
surrounded by a single layer of cells; ii) the secondary and tertiary follicles with more than one 384 
granulosa layers; iii) the small antral (0.3-2 mm), antral (2-6 mm) and the pre-ovulation 
follicles more than 6 mm in diameter, in which the oocytes were surrounded by cumulus cells 386 
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and formed COC. AURKA was poorly detectable in the primary follicles (figure 3A
 a), in the 
secondary follicles (figure 3A
 b) and in the tertiary pre-antral follicles (figure 3A c). In small 388 
antral follicles of about 0.3-0.6 mm in diameter, AURKA immunostaining clearly appeared in 
the cytoplasm of oocytes, which achieved more than 80% of the size of a full-grown oocyte 390 
(figure 3A d). AURKA was also detected in some cumulus, granulosa and theca cells in the 
actively growing follicles (figure 3A d, f) and to a lesser extent in the large follicles (figure 3A 392 
g). No staining was detected without the first antibody (figure 3A e). Along with the follicular 
antrum growth, AURKA staining increased in the oocyte, being excluded from the nucleus 394 
(figure 3A f, g). In all analyzed oocytes originated from antral follicles, AURKA was detected 
exclusively in the cytoplasm.   396 
By western blot, we showed that AURKA protein level increased during IVM, then this level 
remained stable up to the morula stage, and in the expanded blastocyst AURKA level was 398 
significantly declined (figure 3B, black bars). In parallel, we quantified AURKA 
polyadenylated mRNA in oocytes and embryos (figure 3B, grey bars).  The level of polyA 400 
mRNA encoding AURKA was relatively stable in immature, mature and fertilized oocytes, 
then it slightly and progressively decreased during three first cleavages (2C, 4C, 5-8C) and it 402 
fell tremendously in embryos at the morula and blastocyst stages. 
Immunofluorescence showed that AURKA was equally abundant in the cytoplasm of the 404 
unfertilized and fertilized oocytes and in 2C and 4C embryos (figure 3C) and was not 
concentrated significantly in the spindle poles. We observed the concentration of AURKA in 406 
the spindle poles only from the third embryo cleavage (5/8-Cell). At this stage and onward, 
AURKA appeared concentrated to the spindle poles and to the nearest spindle microtubules in 408 
all mitotic blastomers going through pro-metaphase, metaphase and anaphase (8-Cell and 
morula on figure 3C and blastocyst on figure 2 p).    410 
Thus, AURKA accumulated at a very high level in the oocyte cytoplasm during the 
final follicular growth and maturation. AURKA was Thr-phosphorylated in oocytes. 412 
AURKA protein was not degraded up to the embryo genome activation. AURKA was 
definitely relocated to the spindle poles only from 8-Cell stage, i.e. from the moment of 414 
the maternal-embryo transition.  In order to determine the role of AURKA in oocyte, 
we followed the expression of this kinase simultaneously with the several main actors 416 
implicated in the meiotic progression in vitro.  
 
418 
Expression of AURKA, CPEB, MOS, CCNB1 and CDC2  in bovine oocyte during IVM. 
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Once retired from the antral follicles and put into IVM culture medium, bovine oocytes passed 420 
through the sequential stages of nuclear maturation, and then they finally attained the MII and 
were arrested at that stage. In our conditions, the recovered oocytes were in the meiotic 422 
prophase and kept the intact GV for at least 6 hours, as was confirmed by lamin A/C 
immunostaining (not shown). First GVBD occurred at around 6 hours of IVM and the MI stage 424 
was achieved at 10 hours of IVM. At 22 hours, most of the oocytes were at the MII (figure 
4A).  We quantified polyA mRNA levels of AURKA, CCNB1, MOS, CDC2 and CPEB in 426 
oocytes at 3, 6, 10 and 22 hours of IVM by using real-time PCR performed on oligo(dT)-
extended cDNA (figure 4B). In this experiment, in order to prevent cytoplasmic 428 
polyadenylation of oocyte mRNA before IVM, the reference immature oocytes (0h, white bars) 
were retrieved from the ovaries transported at 4°C and were manipulated at 4°C up to RNA 430 
extraction. Total RNA level did not significantly changed during IVM as it was evidenced by 
18S rRNA quantification. Levels of polyA AURKA, CCNB1, CDC2 and CMOS mRNA 432 
increased during the first 3 hours of IVM and from this time onward they were relatively stable 
up to 10h of IVM. After 22h of IVM, AURKA polyA mRNA level did not changed as 434 
compared to 0h, while those of CDC2 was significantly diminished. CCNB1, CPEB and CMOS 
mRNA levels were slightly decreased in MII oocytes (figure 4B).  436 
We quantified AURKA, CCNB1, CPEB and CDC2 protein's levels in the oocytes at the same 
time of IVM (figure 4C). AURKA and CCNB1 increased significantly during maturation. Two 438 
closely migrated shifted AURKA bands were detected in the oocytes throughout IVM (figure 
4D) that might be a consequence of AURKA phosphorylation. For this experiment, the special 440 
sampling and SDS-PAGE procedures were used as described [46].  In contrast to AURKA, 
CCNB1 was not detectable before IVM and its appearance coincided with the phosphorylation 442 
of MAPK3/1 at 3h of IVM (figure 4C). CDC2 protein was maintained at the relatively constant 
level throughout IVM (figure 4C). CPEB was stable in immature oocytes up to GVBD (6h of 444 
IMV), then it declined at 10h and was mostly degraded at 22h of IVM.  The lower migrating 
CPEB-immunoreactive shifted band was detected at 6 and 10 hours of IVM (figure 5A). We 446 
performed the λ-PPase treatment of the oocytes at 10h of IVM and demonstrated that this 
lower migrating band corresponded to the hyper-phosphorylated form of CPEB (figure 5B). 448 
The double immunofluorescence demonstrated that both AURKA and CPEB localized to the 
oocyte cytoplasm (figure 5C). CPEB was fewer detected in the cytoplasm of the mature oocyte 450 
(MII) as compared with the immature oocyte (GV).  However, in MII oocytes CPEB was 
clearly detected at the region of the polar body separation, which might be a contractile ring / 452 
midbody (figure 5C, insert PB).  
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Effect of Roscovitine, U0126 and Metformin on oocyte maturation. 454 
Addition of 50 µM of Roscovitine, a specific inhibitor of CDC2/MPF activity, arrested the 
oocytes at the GV stage after 22h of IVM, but neither significantly influenced the accumulation 456 
of AURKA (figure 5D) nor AURKA phosphorylation as detected by immunofluorescence 
(figure 5E, d) and by gel shift (Supplementary data, figure 2). The phosphorylation of MAP 458 
kinases was inhibited by the addition of specific MAPK kinase inhibitor U0126 (100µM). The 
U0126-treated oocytes overcame the GVBD but did not progress to MII after 22h IVM (figure 460 
5D). Nevertheless, the accumulation of AURKA was neither significantly affected, nor did we 
observe any loss of phospho-Thr- AURKA labelling in U0126 oocytes (figure 5E, f). In 462 
contrast the addition of 10 mM of metformin, an insulin-sensitizing agent and an activator of 
AMPK (Adenosine Monophosphate-Activated kinase), arrested the oocytes before GVBD and 464 
decreased significantly AURKA synthesis and the level of phospho-AURKA 
immunofluorescence (figure 5D and 5E e). The level of phospho-MAPK3/1 was significantly 466 
reduced in the presence of Roscovitine, U0126 or metformin. In contrast, CPEB level was not 
diminished after 22h of IVM in the oocytes treated with Roscovotine, U0126 or metformin, 468 
although in the control IVM experiments, without inhibitors or with DMSO, CPEB was largely 
degraded in mature oocytes (figure 5D). 470 
Thus, in bovine oocytes, the inhibition of MPF or MAPK activation during IVM stopped 
meiosis before the first division.  These treatments had no effect on AURKA accumulation and 472 
activation, but AURKA depletion by the metformin coincided with an arrest at GV. 
Interestingly, all tested inhibitors decreased the level of phospho-MAPK3/1 at 22h of IVM, and 474 
CPEB was neither hyper-phosphorylated nor degraded.  
 476 
Effect of Aurora kinases inhibitor VX680 on oocyte maturation.  
We performed IVM either in the presence of VX680, a small molecule inhibitor for Aurora 478 
kinase activity, or with DMSO as a control. VX680 is a potent inhibitor for AURKA, AURKB 
and AURKC with apparent inhibition constant values of 0.6, 18 and 4.6 nM, respectively [37]. 480 
After IVM, oocytes were denuded from the cumulus cells and nuclear status of oocytes was 
monitored by the chromatin Hoechst staining. When 1 µM concentration of VX680 was used, 482 
72.4% of oocytes were arrested before the MI stage whereas 85% of control oocytes were 
already in MII. In VX680-treated oocytes, no phospho- Ser10 Histone H3 staining was detected 484 
in a compact clump of condensed chromosomes, whereas in control oocytes the phospho-Ser10 
histone H3 was associated to the metaphase chromosomes and to the polar body chromatin 486 
(figure 6A). Practically all the VX680-treated oocytes passed through the GVBD, while no 
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lamin A/C staining was detected around the chromatin (not shown). In the presence of  lower 488 
concentration of VX680 (100 nM), all the oocytes continued meiosis from MI onward and 
phospho- Ser10 Histone H3 was detected associated with the chromatin (figure 6A).  However, 490 
many oocytes demonstrated the abnormal meiosis and showed the over-numerated chromatin 
structures after VX680100nM treatment (Table 2, figure 6B). After 14h of IVM, the control 492 
oocytes were mostly at the MI (figure 6B a), while in VX680-treated oocytes, several 
chromatin groups were detected into the cytoplasm (figure 6B b, c, d). Abnormally large, either 494 
non-extruded (figure 6B c) or over-numerated (figure 6B b) polar bodies were observed in 
VX680100nM -treated oocytes. The chromosomes were sometimes completely disorganized and 496 
dispersed in the cytoplasm (figure 6A d).  After 24h of IVM, the most of the control oocytes 
were at the MII stage (figure 6B e). In contrast, the multiple chromatin structures, similar to the 498 
activated pronucleus or to the non-extruded doubling polar bodies, were detected in 
VX680100nM -treated oocytes (figure 6B f, g, h). Quantification of several polyA transcripts 500 
revealed after 3h of IVM the decrease of only MOS mRNA level in VX680-treated oocytes as 
compared to the control oocytes (figure 6C). By Western blot no differences were detected in 502 
AURKA, CDC2 or phospho-MAPK3/MAP1 protein levels between VX680100nM -treated and 
control groups (figure 6D). In contrast, yet CPEB was detectable in the control oocytes after 504 
14h of IVM, in VX680100nM -treated oocytes CPEB was already degraded.  
 506 
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DISCUSSION 508 
Aurora kinases in bovine oocyte: AURKB and AURKC were localized as in mitotic cells 
while AURKA had a different expression pattern.  510 
We have shown experimentally that three Aurora kinases are expressed in bovine oocytes, and 
that AURKA is more prevalent in immature oocytes in comparison to the other Aurora kinases. 512 
Immunofluorescence and immunoblot analysis indicated that in maturing oocytes Aurora 
kinases were present in the cytoplasm and AURKA and AURKB levels increased during IVM. 514 
In human oocytes also, the level of AURKC mRNA was higher in MI and MII compared to 
immature oocytes [35]. Moreover, we found that AURKB, AURKC and the active Thr-516 
phosphorylated AURKA were concentrated in the contractile ring/midbody zone, located at the 
furrow separating the first polar body. The contractile ring is an actomyosin-based structure 518 
essential for the completion of cytokinesis that is formed on the central spindle in early 
anaphase with the bundling of overlapping microtubules. These bundles become compacted 520 
and mature into the midbody (for review [47]). AURKB is a component of the central spindle 
assembly complex and it phosphorylates another component, Kinesin-6 protein MKLP1, in 522 
vitro and in vivo [48]. Recent studies reported the colocalization of AURKC with 
AURKB/Survivin complex in HeLa cells during mitosis [25]. Thus, the detection of bovine 524 
AURKB and AURKC in the midzone between the ooplasm and the first polar body is 
consistent with their expression pattern in the mitotic cells. More surprisingly, phospho-526 
AURKA was also found in this zone, and this indicates that AURKA might have downstream 
substrates on at this site. Thus, in bovine oocytes, Aurora kinases might participate in the 528 
regulation of the first polar body extrusion.  
AURKB in bovine oocyte was detected to be bound to the metaphase chromosomes in meiosis 530 
I and II, but neither to the chromatin in GV nor in polar body. This hypothesised the role of 
AURKB in the correct alignment and segregation of the chromosomes during meiotic divisions 532 
similarly to mitotic cells. These results were in concordance with the data showing that in 
porcine oocytes AURKB was not involved in chromosome condensation during the first 534 
meiosis while the chromosomes were condensed even upon the inhibition of AURKB and 
Histone H3 phosphorylation [34]. In contrast, AURKA followed the typical expression pattern 536 
of maternal mRNA, i.e. it was accumulated during oogenesis and its level was diminished after 
the maternal-embryo transition. AURKA protein was detected in oocytes from small antral 538 
follicles simultaneously with the appearance of the antrum and with basal follicular growth. 
The signals for antrum formation are not well understood, but in vitro studies performed with 540 
rodent follicles showed that FSH, LH, KL (kit ligand) and EGF are possible candidate 
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regulators (for review [49]). These signals may be also involved in the regulation of AURKA 542 
expression in the bovine oocyte. In cows, the antral follicles up to 5 mm in size are not yet 
dependent on gonadotropins. Progesterone and androgens are likely the main steroid hormones 544 
produced by theca cells, since granulosa cells lack the expression of P450 aromatase, 
converting steroids to estrogens [49]. In frog oocytes, progesterone induces AURKA 546 
accumulation and activation [11, 46]. It is not known whether progesterone or other factors 
induced the initial translation of AURKA in bovine oocytes. However, our data suggests that 548 
accumulation of AURKA in oocyte cytoplasm starts a long time before the ovulation and the 
activated form of this kinase was detected in GV oocytes retrieved from follicles that exceeded 550 
3 mm. In Xenopus oocytes, it was shown that the upper band from two closely migrating bands 
revealed by the AURKA antibody corresponds to Thr-phosphorylated AURKA [30], [50]. 552 
Phosho-AURKA in Xenopus oocytes was detected at GVBD [50,51], while in bovine oocytes 
the shifted AURKA bands were already present in immature GV oocytes and also later during 554 
IVM. Immunofluorescence detection of Thr-phosphorylated AURKA confirmed that active 
Aurora A kinase was present before the GVBD in bovine oocytes.  556 
Thr-phosphorylated AURKA showed an intriguing cytoplasmic localization during meiosis in 
bovine oocyte. Phosphorylated AURKA was visible on the surface and dispersed in the 558 
ooplasm of immature oocyte but was absent from the spindle zone in oocytes at MII, whereas, 
the pan-AURKA eventually concentrated around the MII aligned chromosomes. Perhaps 560 
inactive AURKA participates to the prevention of premature mitotic divisions of unfertilized 
oocytes and thus maintains MII arrest. The absence of the active maternal centrosomes in the 562 
spindle poles in bovine and human oocytes could also explain why AURKA was not 
concentrated on the spindle poles [52]. In contrast, AURKA was located to the spindle in 564 
mitotic blastocyst cells and was Thr-phosphorylated at the spindle poles. The concentration of 
AURKA in the spindle poles was clearly observed in all mitotic cells in bovine embryos from 566 
8-Cell stage, i.e. at the stages when the novel embryo genome was already active [53].   
Whereas AURKA mRNA disappeared progressively in the early embryo, and the AURKA 568 
protein level was stable up to the morula stage and was no longer significantly detectable in the 
blastocyst. The same was observed in Xenopus embryos, where the protein level was stable 570 
during several cleavages while AURKA activity oscillated. In contrast, in somatic cells, 
AURKA protein level peaked at G2/M stage and was degraded during the cells exit from 572 
mitosis. Indeed, destruction of AURKA and several other mitotic regulators, such as cyclins, 
requires an activator of the ubiquitin ligase APC/C (anaphase-promoting complex/cyclosome) 574 
called Cdh1 (for review [54]). However, in Xenopus eggs and early embryos, Cdh1 is missing, 
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and consequently AURKA is not degraded during the initial cleavages [55]. APC/C 576 
recognition sequences, the destruction-boxes, the D-box and A-box are all conserved in 
Xenopus and human Aurora genes [56], [55]. A putative A-box required for the Cdh1-578 
dependent destruction was found within bovine AURKA amino acid sequence, in a similar to 
way to the human, mice and frog genes homologues (Supplementary data, figure 1B).  In mice, 580 
Cdh1 is already present in MII oocytes and some APCCdh1 substrates begin to degrade from the 
second polar body extrusion [57]. Taking in account that in mice, embryos are transcriptionally 582 
active at the late one-cell stage, bovine embryos at the eight-cell stage, and frog after 12 
cleavages at midblastula, we could hypothesize that in bovine oocytes, maternal AURKA was 584 
required to be produced and to be activated in order to accomplish its role up to maternal-
embryo transition, after which it might be destroyed via the APCCdh1 mechanism.  586 
Therefore, the high concentration of active Aurora A in cytoplasm of fully grown immature 
bovine oocytes is probably required for the distinct functions related to the progression of 588 
meiosis similarly to those in frog and mice (review [18]).  Thus, AURKA expression was 
followed throughout IVM in parallel with the main actors of meiotic progression.  590 
AURKA synthesis and phosphorylation was independent from MAPK and MPF 
activation but was not required for CPEB hyper-phosphorylation during IVM.  592 
An increase in the MOS, CCNB1 and CDC2 polyadenylated mRNA levels was observed 
during the first 3 hours of IVM and the subsequent appearance of CCNB1 protein. Our results 594 
were in agreement with the reported RACE-PAT analysis, which showed that the CCNB1 
mRNA polyA tail was progressively elongated during the first 10h of IVM and CCNB1 was 596 
synthesized from the transcripts with a long polyA [58]. MOS protein was produced in bovine 
oocytes from around the onset of meiotic resumption, and became phosphorylated at GVBD 598 
[59]. In pig oocytes, although MOS transcripts were polyadenylated, their translation was 
repressed before GVBD and then increased steadily from MI to MII [60]. According to the 600 
data, AURKA protein was already present in the active phosphorylated form and was localized 
together with CPEB in the cytoplasm of immature oocytes, i.e. before the massive translation 602 
of CCNB1 and MOS. AURKA level increased up to MI, and CPEB became hyper-
phosphorylated at that time. MOS, CCNB1, CDC2 and AURKA mRNAs contain the CPE in 604 
their 3’-UTRs. Thus, AURKA might be potentially implicated in the regulation of 
polyadenylation-dependent translation of these transcripts during oocyte maturation via its 606 
participation in the activation of CPEB as in Xenopus and mouse [11,13,15,30,61]. CPEB is a 
highly conserved RNA binding protein [62] which is a general regulator of meiosis. In CPEB 608 
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knock-out mice oogenesis and spermatogenesis were disrupted at pachytene [63]. In Xenopus 
laevis, phosphorylation of CPEB by Aurora A was reported to trigger the interaction of CPEB 610 
and CPSF, which in turn binds to the AAUAAA sequence and recruits poly(A) polymerase to 
the end of mRNA and therefore regulate the polyadenylation-dependent translation of CPE-612 
containing transcripts (for review see [8]). It was also reported, that in human and rat cell lines 
the over-expression of recombinant AURKA induced the phosphorylation of CPEB and 614 
promoted the polyadenylation of CCNB1 and CDK1/CDC2 mRNAs [64]. In mice oocyte, 
AURKA was reported to phosphorylate CPEB first at leptotene stage of prophase and then at 616 
MI, initially triggering the translation of SCP1/SCP3 and then MOS/CCNB1, respectively [61]. 
We found that AURKA was active in prophase oocytes and was thus potentially capable of 618 
phosphorylating CPEB at a key serine residue in order to activate its functions during this 
period. Moreover, the gel shift of the CPEB band due to high phoshorylation at several 620 
residues was observed during the GVBD-MI transition (6-10h of IVM), prior to the partial 
degradation of CPEB during MI/MII transition and the relocation of remnants to the contractile 622 
ring/midzone.  The fact that CPEB colocalizes with phospho-AURKA at the contractile 
ring/midzone might indicate the local translation/activation of MOS, CCNB1/CDC2 or other 624 
substrates.  In synchronized HeLa cells, AURKA was shown to participate to the recruitment 
of the CCNB1/CDC2 complex to centrosomes, where MPF becomes activated and commits 626 
cells to mitosis [65]. In Xenopus, once the polyadenylation took place during oocyte 
maturation, most of CPEB was destroyed and all that remained stable was confined to the 628 
animal pole blastomeres in embryos where it was strongly associated with the spindle and 
centrosomes and was involved in the localization of CCNB1 mRNA to the mitotic apparatus 630 
[66]. Intriguingly, all tested meiotic inhibitors blocked CPEB hyper-phosphorylation and 
degradation, although the levels of AURKA and Thr-phosphorylation were not significantly 632 
affected, as observed during Roscovitine or U0126 treatment. The arrest prior to MI and the 
decrease of MAPK3/1 phosphorylation were the most common effects of Roscovitine, U0126 634 
and metformin on oocytes after 22h of IVM. Therefore, active MAPK might be involved in 
CPEB hyper-phosphorylation and its consequent degradation. In fact, a recent study reported 636 
that MAPK activation is required for the phosphorylation of CPEB during meiosis in Xenopus 
oocytes and a lower level of MAPK activation was detected prior to MOS synthesis [50].  638 
A significant decrease in AURKA level was observed in metformin-treated oocytes with 
subsequent meiotic arrest at GV stage and this was accompanied by the complete depletion of 640 
CCNB1 synthesis and a significant decrease in MAPK phosphorylation. Metformin inhibits 
protein synthesis through the eEF2 kinase/eEF2 axis and/or the p70S6 kinase pathway [67]. In 642 
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porcine oocytes, metformin also provoked meiotic arrest [68]. Interestingly, metformin was 
recently reported to be an AMPK-dependent growth inhibitor for breast cancer cells [69], 644 
where AURKA is also known to be over-expressed [26,70]. AMPK is present in bovine 
oocytes and cumulus cells [36], and it would be interesting to know whether there is functional 646 
relation between AMPK and AURKA. Although non-specific, the depletion of AURKA by 
metformin in bovine oocytes resulted in the arrest of meiotic progression. In Xenopus oocytes, 648 
the ablation of AURKA protein by the microinjection of a specific antibody also blocked 
meiosis, but the oocytes were arrested at MI [71].  650 
In contrast to CCNB1 and MOS, CDC2 was already present in immature bovine oocytes, and 
no variation in protein quantity was observed during maturation, consistent with previous 652 
reports [6, 72]. This suggests that CDC2 mRNA should be polyadenylated and translated 
during oogenesis earlier that CCNB1 and MOS. In human cells, containing DNA damage and 654 
arrested at G2/M, the over-expression of AURKA triggered an override of the G2/M arrest 
through a CDK1/CDC2 reactivation, suggesting the existence of a retroactive control loop 656 
between AURKA and CDK1 [73]. In frog oocytes, it was also shown that active CDC2 was 
necessary for AURKA activation [14,46,74]. Our results showed that AURKA was 658 
phosphorylated before the activation of MPF and MAPK3/1, and before GVBD. Moreover, the 
inhibitors for CDC2/MPF or MAPK3/1 activity (Roscovitine or U0126 respectively) did not 660 
change the AURKA and phospho-Thr-AURKA expression pattern during IVM. These data 
confirmed that AURKA accumulation and phosphorylation was independent of MPF or MAPK 662 
activation in bovine oocytes as this has been shown in other models [30].   
   664 
Effect of the Aurora kinase activity inhibitor VX680 on the meiotic progression of 
oocytes.  666 
VX680 blocks the kinase activity of all three Aurora kinases, although it shows the greatest 
selectivity for AURKA [37]. In human cells, VX680 inhibits cell proliferation, induces DNA 668 
endoreduplication, tetraploidization and leads to apoptosis [37,75]. In our experiments, oocytes 
treated with 1 µM VX680 resumed GVBD but did not proceed to MI. Since the histone H3 was 670 
not phosphorylated in VX6801µM -treated oocytes, AURKB was probably inhibited at that 
concentration together with AURKA and AURKC. Similarly, in porcine oocytes, Aurora 672 
kinase inhibitor ZM447439, more specific for AURKB, prevented both the activation of 
AURKB and phosphorylation of histone H3 on Ser10. ZM447439-treated oocytes were arrested 674 
just after GVBD in the late diakinesis stage [34]. Although AURKB is not required for 
chromosome condensation [34], it is required for maintenance of chromatin condensation in 676 
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Xenopus [76] and surf clam oocytes [77], and thus AURKB activity might be critical for the 
correct MI/MII transition.  678 
At a concentration of 100 nM, VX680 neither significantly affected the Ser10-phosphorylation 
of histone H3 nor blocked progression through meiosis. Therefore, AURKB might not be 680 
completely inactivated. However, the abnormal meiotic events, including chromosomes 
misalignment, chromatin decondensation and formation of pronucleus-like structures were 682 
observed. Oocytes treated with 100 nM of VX680 seemed to “accelerate” meiosis since polar 
bodies (often non-extruded) were already detected, whereas most of the control oocytes were 684 
only at MI after 14h of IVM. In fact, pronucleus-like chromatin structures were detected within 
the cytoplasm of VX680100nM -treated oocytes whereas the control oocytes were at MII. The 686 
same observation has been made in Xenopus oocytes in which AURKA activity was inhibited 
[78]. While in VX680-treated oocytes MOS polyA mRNA was diminished, it could be 688 
presumed that due to the lower level of MOS protein, the oocytes might enter the 
parthenogenesis. Indeed, oocytes derived from MOS-deficient female mice (MOS-/-) fail to 690 
arrest at MII and undergo parthenogenetic activation [79]. Similarly, bovine and porcine 
oocytes, in which the endogenous MOS mRNA was depleted with double-strand or antisense 692 
RNA microinjections, were partenogenetically activated [80-82]. VX680 also disturbed 
cytokinesis, and this resulted in oocyte “polyploidy”.  Intriguingly, CPEB was more rapidly 694 
degraded in VX680-treated oocytes, but the factors which are responsible for it degradation are 
not known. CPEB was probably already activated before the oocytes were recovered from the 696 
follicles, thus the polyadenylation of CCNB1 might be initiated before IVM as reported in 
bovine species [58], and therefore the maturation progressed and GVBD occurred. However, 698 
MOS protein must be synthesised after GVBD in order to maintain the metaphase-II arrest as a 
component of the cytostatic factor  [83,84]. It could be supposed that while kinase activity of 700 
AURKA was at least partially inhibited by VX680, MOS might not be synthesized at a high 
enough level at this time, and therefore oocytes exited from MII and began DNA replication.  702 
In conclusion, three Aurora kinases are expressed during meiosis in bovine oocytes. 
AURKA, AURKB and AURKC show distinct expression patterns during IVM but localize 704 
together to the midbody during the first polar body extrusion. Meiotic divisions and polar body 
extrusion were affected by the Aurora kinase activity inhibitor. Therefore, Aurora kinases 706 
might play a role in chromosome segregation as in mitotic cells, but also an oocyte-specific 
role in metaphase-II maintenance. Besides which, AURKA is highly expressed and 708 
phosphorylated in immature oocyte cytoplasm where CPEB also localizes. Nevertheless, the 
presence of active AURKA was not sufficient to produce the CPEB hyper-phosphorylation 710 
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observed at MI. Altogether, these observations might indicate the putative involvement of 
AURKA in regulating polyadenylation-dependant translation in bovine oocytes, although this 712 
role will have to be demonstrated by further studies.   
 714 
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FIGURE LEGENDS 
 
Figure 1. Aurora kinases mRNA in bovine oocyte and embryo.  
A. Detection of Aurora kinases genes expression in bovine immature oocytes (Oo), ovary (Ov) 
and testis (Te) by RT-PCR. Total DNAse-treated RNA from testis and ovary (1 µg each) and 
from ten isolated full-grown immature GV oocytes was reverse transcribed.  1% of cDNA was 
used to detect either AURKA, AURKB and AURKC or β-actin (ACTB) expression by 
performing 36 or 32 PCR cycles, respectively. RT-omitted RNA from testis and ovary (125 ng) 
was used as negative control (-).  
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B. AURKA, AURKB and AURKC polyA mRNA levels measured by RT-qPCR in immature 
oocytes, embryos at the blastocyst stage and in testis. RT were performed on RNA from 10 
oocyte/embryo using oligo-dT(15) and real time PCR was run in duplicates using 0.5 % of 
cDNA per reaction. Serial dilution of plasmid DNA containing AURKA, AURKB or AURKC 
partial cDNA were used for quantification standard. Mean quantities +/- SEM of four different 
cDNA samples are presented in fg per ovocyte/embryo and in fg per microgram of testicular 
RNA. Different small letters indicate significant difference in oocytes and embryos, and 
different capital letters indicate significant difference in testis (p<0.05).   
C. Bovine AURKA, AURKB and AURKC proteins detection by Western blot.  
Total proteins were extracted from immature oocytes (IO), mature oocytes 22h after IVM 
(MO), cumulus cells (CC), bovine fibroblasts (Fb), ovary (Ov) and adult testis (Te) biopsies 
and then subjected to SDS-PAGE and immunoblot. Monoclonal antibodies to human Aurora A 
detected 46 kDa AURKA protein in bovine oocytes (10 oocytes were loaded) and testis, and 
ARK-2 rabbit polyclonal antibody recognized 40 kDa AURKB protein in fibroblasts, testis and 
mature oocytes (50 oocytes were loaded). AURKC was detected in testis by using the antibody 
to human Aurora C. Control detection of α-tubulin (TUBA) was performed. 
 
Figure 2. AURKA, AURKB and AURKC proteins localization in bovine oocytes during 
meiosis and in blastocyst.  
AURKA, Thr-phosphorylated AURKA, AURKB and AURKC were detected by 
immunofluorescense in bovine GV immature oocytes (a, b, c, e, respectively); in metaphase-I 
(MI) oocytes (f, g, h, i, respectively); in methaphase-II (MII) oocytes (k, l, n, o, respectively). 
AURKA, phospho-AURKA and AURKB were also detected in embryos at blastula stage (p, r, 
respectively). Red (AURKA) or green (phospho-Thr AURKA, AURKB and AURKC) 
fluorescent images were merged with Hoechst blue chromatin staining. For the control, 
specific antibodies were replaced by mouse and rabbit IgG (d). Double-immunofluorescence 
was performed for simultaneous pan-AURKA and phosho-Thr-AURKA detections. In oocytes 
and blastocysts, the metaphase plates (M, MI, MII) are encompassed by white arrows and 
magnified in insert images. Contractile ring between the oocyte and the polar body (PB) in 
telophase-I / MII oocytes (m, n, o) and the midzone (MZ) between two blastomers during 
cytokinesis (r) are encompassed by white arrowheads and are magnified in inserts. Prophase 
(P), metaphase (M) and anaphase (An) cells in blastocyst are magnified in inserts images. 
Insert M labeled by white asterisk in (p) showed the phospho-Thr AURKA labeling at the 
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poles of the metaphase spindle (picture was selected from another blastocyst). Inserts for the 
pictures of the metaphase chromosomes (M, MI, MII) and the polar body (PB)
 
in (k), (l), (m), 
(n), (o), (r) showed either Aurora immunostaining alone or Aurora / chromatin merged images. 
Bars: 0.5 mm.  
Figure 3.  AURKA in bovine ovary during folliculogenesis, in fertilized oocyte and in 
early embryo.  
A. Analysis of AURKA protein expression during folliculogenesis was performed by DAB-
immunoperoxidase staining on paraffin-embedded ovary sections. Images showed primary 
follicles (a), secondary follicle (b), tertiary pre-antral follicle (c), small antral follicle of about 
0.6 mm in diameter (d), large antral follicles exceeded 2.1 mm and 3.4 mm (f and g). Control 
immunostaining was performed by using mouse IgG instead of primary antibodies (e, adjacent 
section to f). Immuno-specific staining is brown. Cell nuclei were stained with hematoxylin.  
Cumulus-oocyte complex (COC), oocyte (Oo), cumulus cells (CC), antrum (At), granulosa 
(Gr) and theca cells (Th) are designated. Grey rectangles encompassed regions which are 
showed magnified on the right. Bars: a, b, c, e – 50 µm; d, f, g, – 500µm.   
B. Analysis of AURKA mRNA expression during the early embryo development was 
performed by relative mRNA quantification by real time RT-PCR (grey bars) and AURKA 
protein level was analyzed by immunoblot (black bars). Representative immunoblot is shown.  
IO – immature germinal vesicle oocyte, MO - mature oocyte at MII, Zyg – fertilized oocyte or 
zygote, 2C - 2 cell embryos, 4C - 4 cell embryos, 5-8C – 5-8 cell embryos, Mor – morulae 
(>16 cells), Bl – expanded blastula. Immunoblots were quantified and results are presented as 
AURKA / TUBA ratio. Mean of four (mRNA) or three (protein) independent quantifications ± 
SEM are presented. Different small letters indicate significant difference in mRNA expression 
and different capital letters indicate significant difference in protein levels (p<0.05).  
C. Detection of AURKA in bovine fertilized oocyte and in early embryos by 
immunoluorescence. In white-framed inserts nuclear blue Hoechst staining showed the number 
of blastomers. Control immunofluorescence was performed with only secondary antibody.  
Regions of particular AURKA concentration are encompassed by the white arrows and the 
magnified pictures are shown below. Spindle poles in pro-metaphase (Pm), metaphase (M) and 
anaphase (An) cells in 8C embryo and morula (lower images) are indicated by the short arrows. 
Bars (A-I): 50 µm. 
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Figure 4.  Analysis of AURKA, CPEB, MOS, CCNB1 and CDC2 expression in bovine 
oocyte during in vitro maturation.  
A. Timing of nuclear maturation in bovine oocytes determined by lamin A/C  and Hoechst 
chromatin analysis of oocytes at different time of IVM culture of COC in our laboratory 
conditions (IVM medium was TCM199 supplemented with 10% of fetal calf serum and 10 
ng/ml of EGF). GV, germinal vesicle; GVBD, germinal vesicle breakdown, MI, metaphase-I, 
MII, metaphase-II.   
B. Real time PCR quantification of relative AURKA, CPEB, CCNB1, CDC2 and MOS  polyA 
mRNA levels in bovine oocytes before or after 3h, 6h, 10h and 22h of IVM. Reference 
immature oocytes (0h, white bars) were retrieved from ovaries transported on ice and 
manipulated in cold medium up to lysis in TriZol reagent in order to prevent the RNA 
polyadenylation. For each time point, RT was performed using oligo-dT and 18S antisense RT 
primer on four independent RNA samples from 10 oocytes each; real time PCR was run in 
triplicates using 0.5 % of cDNA per reaction and median values were considered. Each value 
was normalized by corresponding 18S rRNA abundance (boxed graphic) and represented as 
histograms; level in immature oocytes was considered as one. Mean +/- SEM of four samples 
is presented. Different letters designated significant difference at p<0.05.  
C. Immunoblot detection of AURKA, CPEB, CCNB1, CDC2 and phospho-MAPK3/MAP1 in 
oocytes just before IVM (0h) or after 3h, 6h, 10h and 22h of IVM COC culture.  Denuded 
oocytes (25-50 oocytes per lane) were subjected to western-blot by using consequently 
AURKA, CCNB1, CDC2, CPEB, phospho-MAPK3/MAPK1 and alpha-tubulin (TUBA) 
antibodies on the same membrane. Representative blots from four independent experiments are 
shown. Blots were quantified and protein / TUB ratio is represented as histograms. The results 
are presented as means ± SEM; the values for the immature oocytes are considered as one. 
Different letters designated significant difference (p<0.05).  
D. Immunoblot detection of the AURKA at 1h, 3h, 6h, 10h and 22h of IVM by using the 
special extraction procedure and Anderson SDS-PAGE [46]. 30 oocytes per line were loaded. 
The upper band might represent the AURKA phosphorylated protein.  
 
Figure 5.  Detection of CPEB and AURKA in bovine oocytes at different maturation 
stages and in the presence of meiotic inhibitors during IVM.   
A. Immunoblot detection of co-expression of CPEB and AURKA in oocytes before (0h) or 
after 6h, 10h and 22h of IVM.  Denuded oocytes (30 oocytes per lane) were immunoblotted by 
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using consequently CPEB, AURKA and TUBA antibodies on the same membrane. Note the 
double band revealed by the CPEB antibody at 6h and 10h of IVM.  
B. Detection of phosphorylated forms of CPEB and MAPK1 by a gel-shift. 50 oocytes at 10 
hours of IVM were lysed and either incubated (+) or not (-) with 400 units of
 λ-phosphatase. 
Anderson SDS-PAGE and successive immunoblotting with CPEB, total MAPK1 and phospho-
MAPK1 antibodies were performed. 50 non-treated immature oocytes before IVM (0h) were 
also loaded. TUBA was used as a loading control.  
C. Double-immunofluorescence detection of CPEB (a,d) and AURKA (b) in immature (GV) 
and mature (MII) oocytes. Images of AURKB (b) and CPEB (a) staining are presented 
separately or merged with DNA labelling (c, d). Merged CPEB / DNA detections in MII 
oocyte (d); the region of the contractile ring near the polar body (PB) is encompassed by the 
arrowhead and magnified in the insert. Bars: 50 µM. 
D. Effect of Roscovitine, U0126 and Metformin on AURKA, CCNB1, CPEB, CDC2 and 
phospho-MAPK3/MAPK1 protein levels in oocytes after 22h of IVM. 
Immunoblot detections of proteins were performed in immature oocytes (IO) and in oocytes 
after 22h of IVM. IVM was performed either in usual medium (control), or supplemented with 
5% of DMSO, of with 50µM of MPF inhibitor Roscovitine (Rosco), or with 100µM of 
phospho-MAPK inhibitor U0126, or with 10mM of Metformin (MetF).  Denuded oocytes (25 
per lane) were subjected to immunoblot by using consequently AURKA, CCNB1, CDC2, 
CPEB, phospho-MAPK3/MAPK1 and TUBA antibodies on the same membranes. 
Representative blots from three independent experiments are shown. Presence or absence of 
GVBD / MII (nuclear maturation) is marked by (+) or by (-) respectively.  
E. Immunofluorescence analysis of AURKA Thr-phosphorylation in control oocytes (a, GV 
oocyte before IVM; b, MI oocyte after 10h of IVM; c, MII oocytes after 22h of IVM) and in 
oocytes after 22h of IVM in the presence of 50µM Roscovitine (d, oocytes arrested at GV), 
10mM Metformin (e, oocytes arrested at GV) or 100µM U0126 (f, oocytes arrested at pro-MI). 
In control immunostaining (g), primary antibodies were replaced by mice and rabbit non-
specific IgG.  
 
Figure 6. Effect of Aurora kinase inhibitor VX680 on oocyte maturation.  
A. Immunofluorescence detection of phospho-Ser10 histone H3 and chromatin staining in the 
oocytes after 24 hours of IVM in the presence or not of Aurora kinase inhibitor VX680. 
Oocytes were fixed and stained with phospho-Ser10 histone H3. Left panel - control MII 
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oocyte; middle panel – oocyte after IVM in the presence of 100 nM VX680, the polar body 
was not extruded; right panel – oocyte after IVM in the presence of 1µM VX680, oocyte was 
arrested in pro-MI.   
B. In vitro maturation of bovine COC in the presence or not of 100nM of Aurora kinase 
inhibitor VX680 was performed.  IVM was stopped either 14h or 24h after the beginning, 
oocytes were denuded from cumulus cells and nuclear status of oocytes was monitored by 
staining with Hoechst.  At 14h of IVM control oocytes were mostly at MI (a), while in VX680-
treated oocytes several chromatin groups was detected (b, c, d). At 24h control oocytes were 
mostly at MII (e), and in VX680-treated oocytes chromatin structures similar to activated 
pronucleus were detected (f, g, h). The nuclei of the eventual cumulus cells are noted (cc). 
C. RT-qPCR quantification of AURKA, MOS,  CDC2, and CPEB mRNA after 3 hours of IVM 
in control oocytes (black bars) or in oocytes treated with 100 nM of VX680 (grey bars). For 
each time point, RT was performed on four independent RNA samples from 10 oocytes each. 
Relative mRNA values are presented as mean +/- SEM. Star designates the significant 
difference at p<0.05.  
D. Immature oocytes (IO) and oocytes after 14h and 24h of IVM in the presence or not of 
100nM VX680 were analyzed by western-blot (40 oocytes per line) for AURKA, CDC2, 
CPEB, phospho-MAPK3/MAP1 and α-tubulin (TUBA) proteins.  
 
Figure 1 supplementary data.  Aurora kinases sequences analysis.   
A. Alignment of bovine Aurora kinases AURKA, AURKB and AURKC amino-acid 
sequences. Underline delimits serine-threonine kinase catalytic domains. Catalytic sites are 
black-boxed. B. Comparison of bovine, human and mouse AURKA amino acid sequences   
(GenBank accession numbers: bovine ABC61056, human O14965, mouse P97477). Identical 
amino acids are shaded. Putative APC/C recognition sequences A-box and D-boxes are 
outlined.  
Figure 2 supplementary data. 
A. Immunoblot detection of the AURKA and phospho-MAPK1 during IVM in the presence or 
absence of 50 µM Roscovitine by using the special extraction procedure [46]. Two shifted 
bands of AURKA were detected; the upper band might represent the phosphorylated form.  
  35
Tables 
Table 1.   Oligonucleotide primer sequences 
 
Gene Primer Sequence (5’-3’) Accession 
number 
Product 
size (bp) 
sense TCGGGAGGACTTGGTTTCTT AURKA 
antisense TGTGCTTGTGAAGGAACACG DQ334808 234 
sense GACATCAAGCCTGAGAATCTGC AURKB 
antisense AAGGACAGGGACATTTCAGGG NM_183084 453 
sense TCCTCATAGTAGGTTGCCGCGT AURKC 
antisense TTCCTCGATGGCTCATGACCA XM_870932 156 
sense GCGTGACATCAAGGAGAAGC ACTB 
antisense TGGAAGGTGGACAGGGAGGC 
NM_0010336
18 432 
sense ATGGCTTGGATCTGCTCTCG CDC2 
antisense CATTAAAGTACGGATGATTCAGTGC NM_174016 89 
sense TGGGTCGGCCTCTACCTTTGCACTTC CCNB1 
antisense CGATGTGGCATACTTGTTCTTGATAGTCA BT020128 332 
sense ATGGAGTTCGGGGGCAATAT CMOS 
antisense TAACAGGCTCTCCTTTGAGGA CX951994 328 
sense CACACACTCGGTACTGAGCAT CPEB 
antisense ACACAGAAGCTCCTGGCCAT XM_864691 410 
sense TCATTCTTCGCCAAAAGCACTCTG luc 
antisense AGCCCATATCCTTGTCGTATCCC X84847 149 
sense CGGACCAGAGCGAAAGCATTTG 
antisense GAATAACG CGCCGCATCG 132 18S  
antisense RT TCGCTCCACCAAC 
DQ222453 
 
 
 
 
Table 2. Nuclear status of the oocytes after IVM in the presence or not of 100 nM 
of VX680. 
 
 
 
pro-MI et MI 
oocytes 
oocytes in AnaI-
TeloI-Meta II  
Multi-nuclear 
oocytes 
14h IVM control 83.3% 16.7% 0 
14h IVM + VX680 41.7% 41.7% 16.6% 
24h IVM control 21.7% 78.3% 0 
24h IVM + VX680 25% 40% 35% 
 
Table 2.  Immature bovine COC were cultured either in usual IVM medium or 
supplemented with 100nM of Aurora kinase inhibitor VX680 for 14h or 24h. Part of 
denuded oocytes was used for morphological observation by Hoechst staining of 
chromatin (Fig. 6B). Nuclear status of VX680-treated oocytes was compared within 
each experiment with control IVM oocytes. Twenty four and forty three oocytes were 
stained and analyzed after 14h and 24h IVM, respectively. 
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AURKA MDRCKENCISGPKTAVPLSDGPKRVPVAQQFPSQNPVSVNSGQAQRVLCPTNSSQRVPSQAQKLVSIQKPVQTLKQKPPQAASAPRPVTRPPSNTQKSKQP 101
AURKB MAQ-KENAYPWPYGRQTAQPGLNTLP--------QRVLRKEPVTPSALVLMSRSNAQPTAA--------PGQKVVENSSGTPNIP---------------- 68
AURKC MSH-RGTA------------------------------RKAGGMQHAV-----------AA--------AGQTV----PGAPTA----------------- 30
AURKA QPPAPGNNPEKEVASKQKNEESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHD 202
AURKB
-----------------------KRSFTIDDFEIGRPLGKGKFGNVYLAREKKSHFIVALKVLFKSQIEKEGVEHQLRREIEIQAHLQHPNILRLYNYFYD 146
AURKC
------------------------RRFTVDDFEIGRPLGKGKFGNVYLARLKKNHFIVALKVLFKSQIEKEGLEHQLRRE-EIQAHLQHPNILRLYNYFHD 107
AURKA ATRVYLILEYAPLGAVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEG 303
AURKB RRRIYLILEYAPRGELYKELQKSRTFDEQRTATIMEELADALTYCHAKKVIHRDIKPENLLLGLRGELKIADFGWSVHAPSLRRKTMCGTLDYLPPEMIEG 247
AURKC ARRVYLILEYAPKGELYKALQRSHTFDEQRTATIIEELADALIYCHERKVIHRDIKPENLLLGLMGEVKIADFGWSVHTPSLRRRTTCGTLDYLPPEMIEG 208
AURKA RMHDEKVDLWSLGVLCYEFLVGKPPFEADTYQETYRRISRVEFTFPDCVPEGARDLISRLLKHNPSQRPTLKEVLEHPWIIANSKPSSCQKKESTSKQS 402
AURKB RTHNEKVDLWCIGVLCYELLVGNPPFESASHNETYRRIVKVDLKFPPSVPLGAQDFIYKLLKHNPSERLPLAQVSAHPWVRTHSR--RVLPPSAPQSVP 344
AURKC RTYDEKVDLWCIGVLCYELLVGNPPFESASTSETYRRILKVDLRFPPSMSSGARDLISKLLRFQPLERLPLVRVLEHPWIRAHSQ--RVLPPSVPMAF- 304
A-box
D-box
D-boxD-box
A.
 
bovine  MDRCKENCISGPKTAVPLSDGPKRVPVAQQFPSQNPVSVNSGQAQRVLCPTNSSQRVPSQAQKLVSIQKPVQTLKQKPPQAASAPRPVTRPPSNTQKSKQPQ 102 
human   MDRSKENCISGPVKATAPVGGPKRVLVTQQFPCQNPLPVNSGQAQRVLCPSNSSQRIPLQAQKLVSSHKPVQNQKQKQLQATSVPHPVSRPLNNTQKSKQPL 102 
mice ...MDRCKENCVSRPVKTTVPF-GPKRVLVTEQIPSQNLGSASSGQAQRVLCPSNS-QRVPSQAQKLGAGQKPAP----KQLPAASVPRPVSR-LNNPQKNEQP-  94 
                                                                                                       
bovine  PPAPGNNPEKEVASKQKNEESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDAT 204 
human   PSAPENNPEEELASKQKNEESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDAT 204 
mice    -AASGNDSEKEQASLQKTEDTKKRQWTLEDFDIGRPLGKGKFGNVYLARERQSKFILALKVLFKTQLEKANVEHQLRREVEIQSHLRHPNILRLYGYFHDAT 195 
 
bovine  RVYLILEYAPLGAVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMH 306 
human   RVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMH 306 
mice    RVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSNGELKIADFGWSVHAPSSRRTTMCGTLDYLPPEMIEGRMH 297 
 
bovine  DEKVDLWSLGVLCYEFLVGKPPFEADTYQETYRRISRVEFTFPDCVPEGARDLISRLLKHNPSQRPTLKEVLEHPWIIANS-KPSSCQ-KKESTSKQS 402 
human   DEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPSNCQ-NKESASKQS 403 
mice    DEKVDLWSLGVLCYEFLVGMPPFEAHTYQETYRRISRVEFTFPDFVTEGARDLISRLLKHNASQRLTLAEVLEHPWIKANSSKPPTGHTSKEPTSKSS 395 
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